Product Description
AZD-6234 is a drug candidate being formulation by AstraZeneca in a solution for SC or IV injection. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05511025?term=AZD-6234&draw=2&rank=1)
Mechanisms of Action: Amylin Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Canada, China, Germany, Japan, Poland, Sweden, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 16
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Obesity|Obesity, Morbid|Overweight|Type 2 Diabetes|Weight Loss
Phase 1: Follicular Lymphoma|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07546760 |
D8460C00003 | P1 |
Recruiting |
Follicular Lymphoma |
2027-02-04 |
88% |
2026-04-24 |
Primary Endpoints|Treatments |
NCT06845813 |
D8750C00007 | P1 |
Completed |
Kidney Diseases |
2025-09-30 |
12% |
2025-11-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06151964 |
CONTEMPO | P2 |
Recruiting |
Obesity|Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic|Type 2 Diabetes|Overweight|Weight Loss |
2027-01-29 |
50% |
2026-05-13 |
|
2024-516176-15-00 |
D8460C00004 | P2 |
Recruiting |
Overweight|Obesity, Morbid |
2026-06-18 |
50% |
2025-05-02 |
Treatments |
NCT06851858 |
ARAY | P2 |
Active, not recruiting |
Obesity|Type 2 Diabetes |
2026-05-27 |
50% |
2026-03-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06862791 |
ASCEND | P2 |
Active, not recruiting |
Obesity|Overweight |
2026-05-25 |
50% |
2025-10-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
jRCT2051240175 |
jRCT2051240175 | P2 |
Not yet recruiting |
Obesity |
2026-02-28 |
|||
NCT06595238 |
APRICUS | P2 |
Completed |
Obesity|Overweight |
2025-08-08 |
12% |
2025-12-18 |
Primary Endpoints |
CTR20254912 |
CTR20254912 | P2 |
Active, not recruiting |
Overweight|Obesity, Morbid |
None |
2026-04-23 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20251720 |
CTR20251720 | P2 |
Active, not recruiting |
Obesity, Morbid|Overweight |
None |
2026-04-05 |
Patient Enrollment|Treatments|Trial Status |
|
NCT07017179 |
D8750C00009 | P2 |
Recruiting |
Obesity|Overweight |
2026-08-06 |
12% |
2025-09-27 |
|
jRCT2051240287 |
jRCT2051240287 | P2 |
Not yet recruiting |
Overweight|Obesity |
2026-06-30 |
|||
NCT07013643 |
D8750C00006 | P1 |
Recruiting |
Overweight|Obesity |
2026-12-25 |
88% |
2026-04-14 |
Primary Endpoints |
NCT07220954 |
D8750C00008 | P1 |
Recruiting |
Overweight|Obesity |
2026-09-09 |
88% |
2026-05-19 |
Primary Endpoints|Treatments|Trial Status |
NCT06132841 |
D8750C00002 | P1 |
Completed |
Obesity|Overweight |
2026-02-03 |
88% |
2026-04-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
jRCT2051240086 |
jRCT2051240086 | P1 |
Recruiting |
Overweight|Obesity |
2024-12-31 |
Recent News Events
Date |
Type |
Title |
|---|